BIO Comments: Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access
December 5, 2017
The Biotechnology Innovation Organization (“BIO”) welcomes the opportunity to submit written comments to supplement our previous live testimony to the FDA’s open docket on the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. BIO appreciated the opportunity to participate in FDA’s July 18th public meeting on this important topic and we are happy to supplement the record with these written comments.
BIO also supplemted the comments we filed on September 19, 2017 to better inform the Docket on Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. 1 Following submission of our comments pursuant to the initial closing date, other stakeholder comments were filed that raise issues of significant concern to BIO and our members. To ensure stakeholder interests in this issue are fully and accurately reflected, BIO submits these supplemental comments for FDA’s consideration
Download Full Comments Below
Comment From Biotechnology Innovation Organization BIO (1)
Bio Comments on Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access
In response to their advance notice of proposed rulemaking (ANPRM), BIO submitted comments to the DOJ's National Security Division on implementing the White House Executive Order of February 28, 2024, “Preventing Access to Americans’ Bulk Sensitive…
We, the undersigned, are writing to express our strong concern with a proposed update to the Medicaid Drug Rebate Program. If finalized in its current form, the proposed rule (CMS-2434-P) would impose significant costs to the government and industry…
The Biotechnology Innovation Organization (“BIO”) welcomes the opportunity to submit written comments to supplement our previous live testimony to the FDA’s open docket on the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. BIO appreciated the opportunity to participate in FDA’s July 18th public meeting on this important topic and we are happy to supplement the record with these written comments.
BIO also supplemted the comments we filed on September 19, 2017 to better inform the Docket on Administering the Hatch-Waxman Amendments: Ensuring a Balance Between Innovation and Access. 1 Following submission of our comments pursuant to the initial closing date, other stakeholder comments were filed that raise issues of significant concern to BIO and our members. To ensure stakeholder interests in this issue are fully and accurately reflected, BIO submits these supplemental comments for FDA’s consideration